New combo tackles tough leukemia
NCT ID NCT07283640
First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 2 times
Summary
This early-phase study tests two drugs, blinatumomab and revumenib, given together to adults with a rare and aggressive form of acute lymphoblastic leukemia (ALL) that has a specific genetic change called KMT2A rearrangement. The main goal is to find a safe dose and understand side effects. The study includes people whose cancer has come back or not responded to treatment, as well as older or frail newly diagnosed patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLINATUMOMAB are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New combo aims to wipe out hidden leukemia cells
- New immunotherapy combo aims to treat leukemia without chemo
- New hope for leukemia patients: Chemo-Free treatment shows promise
- New drug combo targets tough leukemia in early trial
- Exercise plus supplement may rebuild muscle in young transplant survivors
- New hope for babies with leukemia: immunotherapy combo trial launches